Osteonecrosis of the jaw and bevacizumab therapy.
Van Poznak
Catherine
C
University of Michigan, Ann Arbor, MI, USA. cvanpoz@umich.edu
D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D004164:Diphosphonates / Q000009:adverse effects*; D004357:Drug Synergism; D005260:Female; D006801:Humans; D015994:Incidence; D007571:Jaw Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D015337:Multicenter Studies as Topic; D009362:Neoplasm Metastasis; D010020:Osteonecrosis / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D004164:Diphosphonates; D000068258:Bevacizumab
Breast Cancer Res Treat. 2010 Jul;122(1):181-8
20361252
Breast Cancer Res Treat. 2010 Jan;119(1):253-4
19585235
Cancer Invest. 2006 Feb;24(1):110-2
16467002
J Clin Oncol. 2009 Nov 10;27(32):5356-62
19805682
Cancer Invest. 2009 Feb;27(2):221-6
19235596
J Bone Miner Res. 2007 Oct;22(10):1479-91
17663640
Cancer Treat Rev. 2008 Aug;34(5):453-75
18423992
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):71-4
19371817
J Am Dent Assoc. 2009 Jul;140(7):864-75
19571050
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):61-70
19371816
Lancet Oncol. 2008 Dec;9(12):1166-72
19038763
Breast Cancer Res Treat. 2009 Aug;116(3):433-9
19521766
Bone. 2009 Jan;44(1):4-10
18948230
J Oral Maxillofac Surg. 2007 Mar;65(3):369-76
17307580